Phaseline

Companies › Nectero Medical

Nectero Medical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Cardiovascular; next expected readout Jun 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Nectero EAST System with Stabilizer Infusion Solution
Locally delivered endovascular treatment for abdominal aortic aneurysm stabilization
–Phase 2Abdominal Aortic AneurysmJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06001918Nectero EAST System with Stabilizer Infusion SolutionPhase 2Abdominal Aortic AneurysmCardiovascularJun 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Rohto Pharmaceutical Beijing Inno Medicine Cell Biopeutics Resources Sdn Bhd TR Therapeutics Kerecis

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.